3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Active not recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Sarcoma
1
Plasma cell
1
Other hematologic neoplasm
1
Genitourinary
1
CNS
1
Conditions
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Glioma
2
Wilms Tumor
1
Waldenstrom Macroglobulinemia
1
Triple Negative Breast Neoplasms
1
Sarcoma, Synovial
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Recurrence
1
Paraproteinemias
1
Osteosarcoma
1
Neuroectodermal Tumors, Primitive
1
Neuroblastoma
1
Neoplasms, Plasma Cell
1
Neoplasms, Neuroepithelial
1
Neoplasms
1
Multiple Myeloma
1
Medulloblastoma
1
Lymphoproliferative Disorders
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Immunoproliferative Disorders
1
Hodgkin Disease
1
Hematologic Diseases
1
Gliosarcoma
1
Interventions
Cyclophosphamide
30
Rituximab
26
Biopsy
23
Specimen Handling
20
Magnetic Resonance Spectroscopy
18
fludarabine
14
Prednisone
13
Vincristine
11
obinutuzumab
10
Lenalidomide
10
Etoposide
10
Doxorubicin
10
Bendamustine Hydrochloride
9
pembrolizumab
7
venetoclax
6
fludarabine phosphate
6
X-Rays
6
Tacrolimus
6
Nuclear Medicine Department, Hospital
6
Dexamethasone
6
Bortezomib
6
trametinib
5
ibrutinib
5
glofitamab
5
acalabrutinib
5
Mycophenolic Acid
5
Gemcitabine
5
Crizotinib
5
Busulfan
5
copanlisib
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Lymphoma
×
CLR1404
×
90 days
×
Clear all
NCT02952508
2026-03-18
CLOVER-WaM
Cellectar Biosciences, Inc.
Phase 2
Active not recruiting
120 enrolled
NCT03478462
2026-03-18
CLOVER-2
Cellectar Biosciences, Inc.
Phase 1
Active not recruiting
30 enrolled